Endosomal gene expression: a new indicator for prostate cancer patient prognosis?

Simple item page
dc.contributor.authorJohnson, I.
dc.contributor.authorParkinson-Lawrence, E.
dc.contributor.authorKeegan, H.
dc.contributor.authorSpillane, C.
dc.contributor.authorBarry-O'Crowley, J.
dc.contributor.authorWatson, W.
dc.contributor.authorSelemidis, S.
dc.contributor.authorButler, L.
dc.contributor.authorO'Leary, J.
dc.contributor.authorBrooks, D.
dc.date.issued2015
dc.description.abstractProstate cancer continues to be a major cause of morbidity and mortality in men, but a method for accurate prognosis in these patients is yet to be developed. The recent discovery of altered endosomal biogenesis in prostate cancer has identified a fundamental change in the cell biology of this cancer, which holds great promise for the identification of novel biomarkers that can predict disease outcomes. Here we have identified significantly altered expression of endosomal genes in prostate cancer compared to non-malignant tissue in mRNA microarrays and confirmed these findings by qRT-PCR on fresh-frozen tissue. Importantly, we identified endosomal gene expression patterns that were predictive of patient outcomes. Two endosomal tri-gene signatures were identified from a previously published microarray cohort and had a significant capacity to stratify patient outcomes. The expression of APPL1, RAB5A, EEA1, PDCD6IP, NOX4 and SORT1 were altered in malignant patient tissue, when compared to indolent and normal prostate tissue. These findings support the initiation of a case-control study using larger cohorts of prostate tissue, with documented patient outcomes, to determine if different combinations of these new biomarkers can accurately predict disease status and clinical progression in prostate cancer patients.
dc.description.statementofresponsibilityIan R.D. Johnson, Emma J. Parkinson-Lawrence, Helen Keegan, Cathy D. Spillane, Jacqui Barry-O'Crowley, William R. Watson, Stavros Selemidis, Lisa M. Butler, John J. O'Leary, and Doug A. Brooks
dc.identifier.citationOncotarget, 2015; 6(35):37919-37929
dc.identifier.doi10.18632/oncotarget.6114
dc.identifier.issn1949-2553
dc.identifier.issn1949-2553
dc.identifier.orcidButler, L. [0000-0003-2698-3220]
dc.identifier.orcidBrooks, D. [0000-0001-9098-3626]
dc.identifier.urihttp://hdl.handle.net/2440/100119
dc.language.isoen
dc.publisherImpact Journals LLC
dc.relation.grantNHMRC
dc.relation.granthttp://purl.org/au-research/grants/arc/FT120100876
dc.relation.granthttp://purl.org/au-research/grants/arc/FT130101004
dc.rightsThis is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
dc.source.urihttps://doi.org/10.18632/oncotarget.6114
dc.subjectProstate cancer; biomarkers; prognosis; endosomal gene expression; mRNA
dc.titleEndosomal gene expression: a new indicator for prostate cancer patient prognosis?
dc.typeJournal article
pubs.publication-statusPublished

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl_100119.pdf
Size:
1.14 MB
Format:
Adobe Portable Document Format
Description:
Published Version
Download

Collections

Medicine publications